Inhibikase Therapeutics, Inc. (IKT) vs Indaptus Therapeutics, Inc. (INDP)
A side-by-side comparison of Inhibikase Therapeutics, Inc. and Indaptus Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IKT
Inhibikase Therapeutics, Inc.
$1.98HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
INDP
Indaptus Therapeutics, Inc.
$2.59HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IKT vs INDP
growth of $100 · dividends reinvested · last 6yIKT -96.6% (-43.2%/yr)INDP -99.5% (-58.0%/yr)IKT compounded faster over this window
Log scale — wide-divergence pair
IKT INDP
IKT vs INDP: by the numbers
- •INDP is the larger company ($293M vs $261M market cap).
Metrics side by side
Valuation
| Metric | IKT | INDP |
|---|---|---|
| P/B ratio | 1.71 | 25.79 |
Profitability
| Metric | IKT | INDP |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -39.55% | -135.62% |
| ROIC | -42.92% | -129.90% |
Growth (annualized)
| Metric | IKT | INDP |
|---|---|---|
| Total return CAGR (5Y) | -29.10% | -58.32% |
Frequently asked
- How have IKT and INDP total returns compared?
- Over the past 5 years, IKT delivered -29.10% and INDP delivered -58.32% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.